ID   LOX5_HUMAN              Reviewed;         674 AA.
AC   P09917; B7ZLS0; E5FPY5; E5FPY7; E5FPY8; Q5JQ14;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   15-MAR-2017, entry version 186.
DE   RecName: Full=Arachidonate 5-lipoxygenase;
DE            Short=5-LO;
DE            Short=5-lipoxygenase;
DE            EC=1.13.11.34;
GN   Name=ALOX5; Synonyms=LOG5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=3422434; DOI=10.1073/pnas.85.2.416;
RA   Dixon R.A.F., Jones R.E., Diehl R.E., Bennett C.D., Kargman S.,
RA   Rouzer C.A.;
RT   "Cloning of the cDNA for human 5-lipoxygenase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:416-420(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2829172; DOI=10.1073/pnas.85.1.26;
RA   Matsumoto T., Funk C.D., Raadmark O., Hoeoeg J.-O., Joernvall H.,
RA   Samuelsson B.;
RT   "Molecular cloning and amino acid sequence of human 5-lipoxygenase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:26-30(1988).
RN   [3]
RP   ERRATUM.
RA   Matsumoto T., Funk C.D., Raadmark O., Hoeoeg J.-O., Joernvall H.,
RA   Samuelsson B.;
RL   Proc. Natl. Acad. Sci. U.S.A. 85:3406-3406(1988).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=2526519;
RA   Matsumoto T., Funk C.D., Raadmark O., Hoeoeg J.-O., Joernvall H.,
RA   Samuelsson B.;
RT   "Molecular cloning and amino acid sequence of human 5-lipoxygenase.";
RL   Adv. Prostaglandin Thromboxane Leukotriene Res. 19:466-469(1989).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4 AND 5).
RX   PubMed=21098726; DOI=10.1096/fj.10-173856;
RA   Boudreau L.H., Bertin J., Robichaud P.P., Laflamme M., Ouellette R.J.,
RA   Flamand N., Surette M.E.;
RT   "Novel 5-lipoxygenase isoforms affect the biosynthesis of 5-
RT   lipoxygenase products.";
RL   FASEB J. 25:1097-1105(2011).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-50.
RX   PubMed=2565035; DOI=10.1073/pnas.86.8.2587;
RA   Funk C.D., Hoshiko S., Matsumoto T., Raadmark O., Samuelsson B.;
RT   "Characterization of the human 5-lipoxygenase gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:2587-2591(1989).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-11.
RX   PubMed=2251250; DOI=10.1073/pnas.87.23.9073;
RA   Hoshiko S., Raadmark O., Samuelsson B.;
RT   "Characterization of the human 5-lipoxygenase gene promoter.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:9073-9077(1990).
RN   [10]
RP   SUBCELLULAR LOCATION.
RX   PubMed=3118366; DOI=10.1073/pnas.84.21.7393;
RA   Rouzer C.A., Samuelsson B.;
RT   "Reversible, calcium-dependent membrane association of human leukocyte
RT   5-lipoxygenase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:7393-7397(1987).
RN   [11]
RP   MUTAGENESIS OF HIS-363; HIS-368; HIS-373; HIS-391 AND HIS-400.
RX   PubMed=1939225;
RA   Nguyen T., Falgueyret J.-P., Abramowitz M., Riendeau D.;
RT   "Evaluation of the role of conserved His and Met residues among
RT   lipoxygenases by site-directed mutagenesis of recombinant human 5-
RT   lipoxygenase.";
RL   J. Biol. Chem. 266:22057-22062(1991).
RN   [12]
RP   MUTAGENESIS OF HIS-368; HIS-373; GLU-377; HIS-391; HIS-400 AND
RP   HIS-551.
RX   PubMed=1540191; DOI=10.1016/0006-291X(92)91901-2;
RA   Ishii S., Noguchi M., Miyano M., Matsumoto T., Noma M.;
RT   "Mutagenesis studies on the amino acid residues involved in the iron-
RT   binding and the activity of human 5-lipoxygenase.";
RL   Biochem. Biophys. Res. Commun. 182:1482-1490(1992).
RN   [13]
RP   SUBCELLULAR LOCATION.
RX   PubMed=8245774; DOI=10.1084/jem.178.6.1935;
RA   Woods J.W., Evans J.F., Ethier D., Scott S., Vickers P.J., Hearn L.,
RA   Heibein J.A., Charleson S., Singer I.I.;
RT   "5-lipoxygenase and 5-lipoxygenase-activating protein are localized in
RT   the nuclear envelope of activated human leukocytes.";
RL   J. Exp. Med. 178:1935-1946(1993).
RN   [14]
RP   PHOSPHORYLATION AT SER-272.
RX   PubMed=11844797; DOI=10.1074/jbc.M111945200;
RA   Werz O., Szellas D., Steinhilber D., Radmark O.;
RT   "Arachidonic acid promotes phosphorylation of 5-lipoxygenase at Ser-
RT   271 by MAPK-activated protein kinase 2 (MK2).";
RL   J. Biol. Chem. 277:14793-14800(2002).
RN   [15]
RP   PHOSPHORYLATION AT SER-524, AND MUTAGENESIS OF SER-524.
RX   PubMed=15280375; DOI=10.1074/jbc.M312568200;
RA   Luo M., Jones S.M., Phare S.M., Coffey M.J., Peters-Golden M.,
RA   Brock T.G.;
RT   "Protein kinase A inhibits leukotriene synthesis by phosphorylation of
RT   5-lipoxygenase on serine 523.";
RL   J. Biol. Chem. 279:41512-41520(2004).
RN   [16]
RP   SUBCELLULAR LOCATION.
RX   PubMed=16275640; DOI=10.1074/jbc.M506513200;
RA   Flamand N., Lefebvre J., Surette M.E., Picard S., Borgeat P.;
RT   "Arachidonic acid regulates the translocation of 5-lipoxygenase to the
RT   nuclear membranes in human neutrophils.";
RL   J. Biol. Chem. 281:129-136(2006).
RN   [17]
RP   INTERACTION WITH ALOX5AP AND LTC4S, AND SUBCELLULAR LOCATION.
RX   PubMed=19233132; DOI=10.1016/j.bbrc.2009.02.074;
RA   Strid T., Svartz J., Franck N., Hallin E., Ingelsson B.,
RA   Soederstroem M., Hammarstroem S.;
RT   "Distinct parts of leukotriene C(4) synthase interact with 5-
RT   lipoxygenase and 5-lipoxygenase activating protein.";
RL   Biochem. Biophys. Res. Commun. 381:518-522(2009).
RN   [18]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-272, AND MUTAGENESIS OF
RP   SER-272.
RX   PubMed=18978352; DOI=10.1074/jbc.M805593200;
RA   Flamand N., Luo M., Peters-Golden M., Brock T.G.;
RT   "Phosphorylation of serine 271 on 5-lipoxygenase and its role in
RT   nuclear export.";
RL   J. Biol. Chem. 284:306-313(2009).
RN   [19]
RP   INTERACTION WITH COTL1, AND MUTAGENESIS OF TRP-103.
RX   PubMed=19807693; DOI=10.1042/BJ20090856;
RA   Esser J., Rakonjac M., Hofmann B., Fischer L., Provost P.,
RA   Schneider G., Steinhilber D., Samuelsson B., Radmark O.;
RT   "Coactosin-like protein functions as a stabilizing chaperone for 5-
RT   lipoxygenase: role of tryptophan 102.";
RL   Biochem. J. 425:265-274(2010).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEX WITH IRON ION,
RP   COFACTOR, CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=21233389; DOI=10.1126/science.1197203;
RA   Gilbert N.C., Bartlett S.G., Waight M.T., Neau D.B., Boeglin W.E.,
RA   Brash A.R., Newcomer M.E.;
RT   "The structure of human 5-lipoxygenase.";
RL   Science 331:217-219(2011).
RN   [21]
RP   VARIANT LYS-254.
RX   PubMed=15308583; DOI=10.1093/carcin/bgh260;
RA   Goodman J.E., Bowman E.D., Chanock S.J., Alberg A.J., Harris C.C.;
RT   "Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX)
RT   polymorphisms and colon cancer risk.";
RL   Carcinogenesis 25:2467-2472(2004).
CC   -!- FUNCTION: Catalyzes the first step in leukotriene biosynthesis,
CC       and thereby plays a role in inflammatory processes.
CC       {ECO:0000269|PubMed:21233389}.
CC   -!- CATALYTIC ACTIVITY: Arachidonate + O(2) = leukotriene A(4) +
CC       H(2)O. {ECO:0000269|PubMed:21233389}.
CC   -!- COFACTOR:
CC       Name=Fe cation; Xref=ChEBI:CHEBI:24875;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU00726,
CC         ECO:0000269|PubMed:21233389};
CC       Note=Binds 1 Fe cation per subunit. {ECO:0000255|PROSITE-
CC       ProRule:PRU00726, ECO:0000269|PubMed:21233389};
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108; Evidence={ECO:0000250};
CC       Note=Binds 2 calcium ions per subunit. {ECO:0000250};
CC   -!- PATHWAY: Lipid metabolism; leukotriene A4 biosynthesis.
CC   -!- SUBUNIT: Interacts with ALOX5AP and LTC4S. Interacts with COTL1,
CC       the interaction is required for stability and efficient catalytic
CC       activity. {ECO:0000269|PubMed:19233132,
CC       ECO:0000269|PubMed:19807693, ECO:0000269|PubMed:21233389}.
CC   -!- INTERACTION:
CC       Q6P2R3:C6orf182; NbExp=3; IntAct=EBI-79934, EBI-12696312;
CC       Q8IYX8-2:CEP57L1; NbExp=3; IntAct=EBI-79934, EBI-10181988;
CC       Q96MT8:CEP63; NbExp=3; IntAct=EBI-79934, EBI-741977;
CC       Q96MT8-3:CEP63; NbExp=5; IntAct=EBI-79934, EBI-11522539;
CC       Q14019:COTL1; NbExp=4; IntAct=EBI-79934, EBI-79926;
CC       P09769:FGR; NbExp=2; IntAct=EBI-79934, EBI-1383732;
CC       P08631:HCK; NbExp=2; IntAct=EBI-79934, EBI-346340;
CC       Q6UWX4:HHIPL2; NbExp=6; IntAct=EBI-79934, EBI-10196655;
CC       Q9Y6D9:MAD1L1; NbExp=8; IntAct=EBI-79934, EBI-742610;
CC       P50221:MEOX1; NbExp=3; IntAct=EBI-79934, EBI-2864512;
CC       Q86Y26:NUTM1; NbExp=3; IntAct=EBI-79934, EBI-10178410;
CC       P17612:PRKACA; NbExp=2; IntAct=EBI-79934, EBI-476586;
CC       Q04864:REL; NbExp=3; IntAct=EBI-79934, EBI-307352;
CC       Q8N0S2:SYCE1; NbExp=6; IntAct=EBI-79934, EBI-6872807;
CC       P07947:YES1; NbExp=2; IntAct=EBI-79934, EBI-515331;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus matrix. Nucleus membrane;
CC       Peripheral membrane protein. Note=Shuttles between cytoplasm and
CC       nucleus. Found exclusively in the nucleus, when phosphorylated on
CC       Ser-272. Calcium binding promotes translocation from the cytosol
CC       and the nuclear matrix to the nuclear envelope and membrane
CC       association.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1;
CC         IsoId=P09917-1; Sequence=Displayed;
CC       Name=2; Synonyms=Delta-13;
CC         IsoId=P09917-2; Sequence=VSP_046998;
CC       Name=3; Synonyms=delta-p10;
CC         IsoId=P09917-3; Sequence=VSP_053534;
CC       Name=4; Synonyms=delta-10-13;
CC         IsoId=P09917-4; Sequence=VSP_053535, VSP_053537;
CC       Name=5; Synonyms=alpha-10;
CC         IsoId=P09917-5; Sequence=VSP_053536;
CC   -!- PTM: Serine phosphorylation by MAPKAPK2 is stimulated by
CC       arachidonic acid. Phosphorylation on Ser-523 by PKA has an
CC       inhibitory effect. Phosphorylation on Ser-272 prevents export from
CC       the nucleus. {ECO:0000269|PubMed:11844797,
CC       ECO:0000269|PubMed:15280375, ECO:0000269|PubMed:18978352}.
CC   -!- SIMILARITY: Belongs to the lipoxygenase family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ALOX5ID42985ch10q11.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J03600; AAA36183.1; -; mRNA.
DR   EMBL; J03571; AAA65450.1; -; mRNA.
DR   EMBL; HM592258; ADR30798.1; -; mRNA.
DR   EMBL; HM592259; ADR30799.1; -; mRNA.
DR   EMBL; HM592260; ADR30800.1; -; mRNA.
DR   EMBL; HM592261; ADR30801.1; -; mRNA.
DR   EMBL; J04520; AAA59522.1; -; Genomic_DNA.
DR   EMBL; AL731567; CAI41243.1; -; Genomic_DNA.
DR   EMBL; BC130332; AAI30333.1; -; mRNA.
DR   EMBL; BC132677; AAI32678.1; -; mRNA.
DR   EMBL; BC143985; AAI43986.1; -; mRNA.
DR   EMBL; M38191; AAA63212.1; -; Genomic_DNA.
DR   CCDS; CCDS58078.1; -. [P09917-2]
DR   CCDS; CCDS7212.1; -. [P09917-1]
DR   PIR; A28117; DAHUAL.
DR   RefSeq; NP_000689.1; NM_000698.4. [P09917-1]
DR   RefSeq; NP_001243082.1; NM_001256153.2. [P09917-3]
DR   RefSeq; NP_001243083.1; NM_001256154.2. [P09917-2]
DR   RefSeq; NP_001307790.1; NM_001320861.1.
DR   UniGene; Hs.89499; -.
DR   PDB; 2ABV; Model; -; A=2-674.
DR   PDB; 3O8Y; X-ray; 2.39 A; A/B=1-674.
DR   PDB; 3V92; X-ray; 2.74 A; A/B=1-674.
DR   PDB; 3V98; X-ray; 2.07 A; A/B=1-674.
DR   PDB; 3V99; X-ray; 2.25 A; A/B=1-674.
DR   PDBsum; 2ABV; -.
DR   PDBsum; 3O8Y; -.
DR   PDBsum; 3V92; -.
DR   PDBsum; 3V98; -.
DR   PDBsum; 3V99; -.
DR   ProteinModelPortal; P09917; -.
DR   SMR; P09917; -.
DR   BioGrid; 106741; 57.
DR   DIP; DIP-30950N; -.
DR   IntAct; P09917; 24.
DR   STRING; 9606.ENSP00000363512; -.
DR   BindingDB; P09917; -.
DR   ChEMBL; CHEMBL215; -.
DR   DrugBank; DB00233; Aminosalicylic Acid.
DR   DrugBank; DB01014; Balsalazide.
DR   DrugBank; DB00586; Diclofenac.
DR   DrugBank; DB00711; Diethylcarbamazine.
DR   DrugBank; DB01892; Hyperforin.
DR   DrugBank; DB04725; Licofelone.
DR   DrugBank; DB00179; Masoprocol.
DR   DrugBank; DB00939; Meclofenamic acid.
DR   DrugBank; DB00244; Mesalazine.
DR   DrugBank; DB01017; Minocycline.
DR   DrugBank; DB05431; MLN-977.
DR   DrugBank; DB00471; Montelukast.
DR   DrugBank; DB00795; Sulfasalazine.
DR   DrugBank; DB00163; Vitamin E.
DR   DrugBank; DB00744; Zileuton.
DR   GuidetoPHARMACOLOGY; 1385; -.
DR   SwissLipids; SLP:000000669; -.
DR   iPTMnet; P09917; -.
DR   PhosphoSitePlus; P09917; -.
DR   BioMuta; ALOX5; -.
DR   DMDM; 126407; -.
DR   EPD; P09917; -.
DR   MaxQB; P09917; -.
DR   PaxDb; P09917; -.
DR   PeptideAtlas; P09917; -.
DR   PRIDE; P09917; -.
DR   DNASU; 240; -.
DR   Ensembl; ENST00000374391; ENSP00000363512; ENSG00000012779. [P09917-1]
DR   Ensembl; ENST00000542434; ENSP00000437634; ENSG00000012779. [P09917-2]
DR   Ensembl; ENST00000610656; ENSP00000484468; ENSG00000275565. [P09917-1]
DR   Ensembl; ENST00000622021; ENSP00000479958; ENSG00000275565. [P09917-2]
DR   GeneID; 240; -.
DR   KEGG; hsa:240; -.
DR   UCSC; uc001jce.5; human. [P09917-1]
DR   CTD; 240; -.
DR   DisGeNET; 240; -.
DR   GeneCards; ALOX5; -.
DR   HGNC; HGNC:435; ALOX5.
DR   HPA; HPA071285; -.
DR   MalaCards; ALOX5; -.
DR   MIM; 152390; gene.
DR   neXtProt; NX_P09917; -.
DR   OpenTargets; ENSG00000012779; -.
DR   PharmGKB; PA46; -.
DR   eggNOG; ENOG410IF0U; Eukaryota.
DR   eggNOG; ENOG410YN4N; LUCA.
DR   GeneTree; ENSGT00550000074415; -.
DR   HOGENOM; HOG000234358; -.
DR   HOVERGEN; HBG005150; -.
DR   InParanoid; P09917; -.
DR   KO; K00461; -.
DR   OMA; MQHWKED; -.
DR   OrthoDB; EOG091G04A4; -.
DR   PhylomeDB; P09917; -.
DR   TreeFam; TF105320; -.
DR   BioCyc; MetaCyc:HS00336-MONOMER; -.
DR   BRENDA; 1.13.11.34; 2681.
DR   Reactome; R-HSA-2142688; Synthesis of 5-eicosatetraenoic acids.
DR   Reactome; R-HSA-2142691; Synthesis of Leukotrienes (LT) and Eoxins (EX).
DR   Reactome; R-HSA-2142700; Synthesis of Lipoxins (LX).
DR   Reactome; R-HSA-6785807; Interleukin-4 and 13 signaling.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SABIO-RK; P09917; -.
DR   SIGNOR; P09917; -.
DR   UniPathway; UPA00877; -.
DR   ChiTaRS; ALOX5; human.
DR   EvolutionaryTrace; P09917; -.
DR   GeneWiki; Arachidonate_5-lipoxygenase; -.
DR   GenomeRNAi; 240; -.
DR   PMAP-CutDB; P09917; -.
DR   PRO; PR:P09917; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000012779; -.
DR   CleanEx; HS_ALOX5; -.
DR   ExpressionAtlas; P09917; baseline and differential.
DR   Genevisible; P09917; HS.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0005635; C:nuclear envelope; IDA:UniProtKB.
DR   GO; GO:0005641; C:nuclear envelope lumen; IDA:UniProtKB.
DR   GO; GO:0016363; C:nuclear matrix; IDA:UniProtKB.
DR   GO; GO:0031965; C:nuclear membrane; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:0004051; F:arachidonate 5-lipoxygenase activity; IDA:UniProtKB.
DR   GO; GO:0005506; F:iron ion binding; IDA:UniProtKB.
DR   GO; GO:0019370; P:leukotriene biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0006691; P:leukotriene metabolic process; TAS:Reactome.
DR   GO; GO:0002540; P:leukotriene production involved in inflammatory response; IEA:Ensembl.
DR   GO; GO:2001300; P:lipoxin metabolic process; TAS:Reactome.
DR   GO; GO:0019372; P:lipoxygenase pathway; TAS:Reactome.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   Gene3D; 2.60.60.20; -; 1.
DR   InterPro; IPR000907; LipOase.
DR   InterPro; IPR013819; LipOase_C.
DR   InterPro; IPR020834; LipOase_CS.
DR   InterPro; IPR020833; LipOase_Fe_BS.
DR   InterPro; IPR001885; LipOase_mml.
DR   InterPro; IPR001024; PLAT/LH2_dom.
DR   PANTHER; PTHR11771; PTHR11771; 1.
DR   Pfam; PF00305; Lipoxygenase; 1.
DR   Pfam; PF01477; PLAT; 1.
DR   PRINTS; PR00087; LIPOXYGENASE.
DR   PRINTS; PR00467; MAMLPOXGNASE.
DR   SMART; SM00308; LH2; 1.
DR   SUPFAM; SSF48484; SSF48484; 1.
DR   SUPFAM; SSF49723; SSF49723; 1.
DR   PROSITE; PS00711; LIPOXYGENASE_1; 1.
DR   PROSITE; PS00081; LIPOXYGENASE_2; 1.
DR   PROSITE; PS51393; LIPOXYGENASE_3; 1.
DR   PROSITE; PS50095; PLAT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Complete proteome;
KW   Cytoplasm; Dioxygenase; Direct protein sequencing; Iron;
KW   Leukotriene biosynthesis; Membrane; Metal-binding; Nucleus;
KW   Oxidoreductase; Phosphoprotein; Polymorphism; Reference proteome.
FT   CHAIN         1    674       Arachidonate 5-lipoxygenase.
FT                                /FTId=PRO_0000220693.
FT   DOMAIN        2    118       PLAT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00152}.
FT   DOMAIN      119    674       Lipoxygenase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00726}.
FT   METAL        17     17       Calcium 1; via carbonyl oxygen;
FT                                structural. {ECO:0000250}.
FT   METAL        18     18       Calcium 2; via carbonyl oxygen;
FT                                structural. {ECO:0000250}.
FT   METAL        19     19       Calcium 2; structural. {ECO:0000250}.
FT   METAL        44     44       Calcium 2; structural. {ECO:0000250}.
FT   METAL        45     45       Calcium 2; via carbonyl oxygen;
FT                                structural. {ECO:0000250}.
FT   METAL        47     47       Calcium 2; structural. {ECO:0000250}.
FT   METAL        79     79       Calcium 1; via carbonyl oxygen;
FT                                structural. {ECO:0000250}.
FT   METAL        80     80       Calcium 1; via carbonyl oxygen;
FT                                structural. {ECO:0000250}.
FT   METAL       368    368       Iron; catalytic.
FT   METAL       373    373       Iron; catalytic.
FT   METAL       551    551       Iron; catalytic.
FT   METAL       555    555       Iron; catalytic.
FT   METAL       674    674       Iron; via carboxylate; catalytic.
FT   SITE        103    103       Essential for stabilizing binding to
FT                                COTL1.
FT   MOD_RES     272    272       Phosphoserine; by MAPKAPK2.
FT                                {ECO:0000269|PubMed:11844797,
FT                                ECO:0000269|PubMed:18978352}.
FT   MOD_RES     524    524       Phosphoserine; by PKA.
FT                                {ECO:0000269|PubMed:15280375}.
FT   VAR_SEQ     424    455       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:21098726}.
FT                                /FTId=VSP_053534.
FT   VAR_SEQ     425    533       ANATGGGGHVQMVQRAMKDLTYASLCFPEAIKARGMESKED
FT                                IPYYFYRDDGLLVWEAIRTFTAEVVDIYYEGDQVVEEDPEL
FT                                QDFVNDVYVYGMRGRKSSGFPKSVKSR -> VHGRGGRHLL
FT                                RGRPGGGGGPGAAGLRERCLRVRHAGPQVLRLPQVGQEPGA
FT                                AVGVPDRGDLHRLRPARRGQLRPAVPGHVPRRAFYREACEG
FT                                SHGPIPQEPRGHCQRDC (in isoform 4).
FT                                {ECO:0000303|PubMed:21098726}.
FT                                /FTId=VSP_053535.
FT   VAR_SEQ     485    674       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:21098726}.
FT                                /FTId=VSP_053536.
FT   VAR_SEQ     534    674       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:21098726}.
FT                                /FTId=VSP_053537.
FT   VAR_SEQ     559    615       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:21098726}.
FT                                /FTId=VSP_046998.
FT   VARIANT     254    254       E -> K (in dbSNP:rs2228065).
FT                                {ECO:0000269|PubMed:15308583}.
FT                                /FTId=VAR_028018.
FT   MUTAGEN     103    103       W->A: Abolishes binding to COTL1.
FT                                {ECO:0000269|PubMed:19807693}.
FT   MUTAGEN     272    272       S->A: Loss of phosphorylation site.
FT                                Permits export from the nucleus.
FT                                {ECO:0000269|PubMed:18978352}.
FT   MUTAGEN     359    359       D->N: No loss of activity.
FT   MUTAGEN     363    363       H->S,N: Still some substantial activity.
FT                                {ECO:0000269|PubMed:1939225}.
FT   MUTAGEN     368    368       H->S,N,A: No activity.
FT                                {ECO:0000269|PubMed:1540191,
FT                                ECO:0000269|PubMed:1939225}.
FT   MUTAGEN     373    373       H->S,N: No activity.
FT                                {ECO:0000269|PubMed:1540191,
FT                                ECO:0000269|PubMed:1939225}.
FT   MUTAGEN     377    377       E->Q: No activity.
FT                                {ECO:0000269|PubMed:1540191}.
FT   MUTAGEN     391    391       H->A: No activity.
FT                                {ECO:0000269|PubMed:1540191,
FT                                ECO:0000269|PubMed:1939225}.
FT   MUTAGEN     391    391       H->S,N: Still some substantial activity.
FT                                {ECO:0000269|PubMed:1540191,
FT                                ECO:0000269|PubMed:1939225}.
FT   MUTAGEN     400    400       H->A: No activity.
FT                                {ECO:0000269|PubMed:1540191,
FT                                ECO:0000269|PubMed:1939225}.
FT   MUTAGEN     400    400       H->S,N: Still some substantial activity.
FT                                {ECO:0000269|PubMed:1540191,
FT                                ECO:0000269|PubMed:1939225}.
FT   MUTAGEN     433    433       H->N,A: Almost no loss of activity.
FT   MUTAGEN     524    524       S->A: Prevents phosphorylation by PKA.
FT                                {ECO:0000269|PubMed:15280375}.
FT   MUTAGEN     551    551       H->N,A: No activity.
FT                                {ECO:0000269|PubMed:1540191}.
FT   STRAND        4     10       {ECO:0000244|PDB:3V98}.
FT   STRAND       20     30       {ECO:0000244|PDB:3V98}.
FT   STRAND       36     38       {ECO:0000244|PDB:3V99}.
FT   STRAND       51     56       {ECO:0000244|PDB:3V98}.
FT   STRAND       64     73       {ECO:0000244|PDB:3V98}.
FT   STRAND       75     77       {ECO:0000244|PDB:3V98}.
FT   STRAND       81     89       {ECO:0000244|PDB:3V98}.
FT   STRAND       95    104       {ECO:0000244|PDB:3V98}.
FT   STRAND      106    108       {ECO:0000244|PDB:3V98}.
FT   STRAND      110    113       {ECO:0000244|PDB:3V98}.
FT   HELIX       120    122       {ECO:0000244|PDB:3V98}.
FT   HELIX       126    142       {ECO:0000244|PDB:3V98}.
FT   STRAND      155    157       {ECO:0000244|PDB:3V98}.
FT   HELIX       161    163       {ECO:0000244|PDB:3V98}.
FT   HELIX       166    168       {ECO:0000244|PDB:3V98}.
FT   STRAND      171    176       {ECO:0000244|PDB:3V98}.
FT   HELIX       178    188       {ECO:0000244|PDB:3V98}.
FT   HELIX       192    194       {ECO:0000244|PDB:3V98}.
FT   HELIX       205    212       {ECO:0000244|PDB:3V98}.
FT   TURN        213    215       {ECO:0000244|PDB:3V98}.
FT   HELIX       218    226       {ECO:0000244|PDB:3V98}.
FT   HELIX       230    239       {ECO:0000244|PDB:3V98}.
FT   HELIX       260    263       {ECO:0000244|PDB:3V98}.
FT   TURN        264    266       {ECO:0000244|PDB:3V98}.
FT   HELIX       273    278       {ECO:0000244|PDB:3V98}.
FT   STRAND      282    286       {ECO:0000244|PDB:3V98}.
FT   HELIX       288    290       {ECO:0000244|PDB:3V98}.
FT   STRAND      297    300       {ECO:0000244|PDB:3V99}.
FT   HELIX       303    306       {ECO:0000244|PDB:3V99}.
FT   STRAND      310    315       {ECO:0000244|PDB:3V98}.
FT   STRAND      321    331       {ECO:0000244|PDB:3V98}.
FT   STRAND      333    336       {ECO:0000244|PDB:3V92}.
FT   HELIX       345    365       {ECO:0000244|PDB:3V98}.
FT   HELIX       366    372       {ECO:0000244|PDB:3V98}.
FT   HELIX       373    386       {ECO:0000244|PDB:3V98}.
FT   HELIX       392    397       {ECO:0000244|PDB:3V98}.
FT   HELIX       398    400       {ECO:0000244|PDB:3V98}.
FT   HELIX       404    414       {ECO:0000244|PDB:3V98}.
FT   HELIX       421    423       {ECO:0000244|PDB:3V98}.
FT   TURN        427    431       {ECO:0000244|PDB:3V98}.
FT   HELIX       432    441       {ECO:0000244|PDB:3V98}.
FT   HELIX       447    449       {ECO:0000244|PDB:3V98}.
FT   HELIX       451    457       {ECO:0000244|PDB:3V98}.
FT   TURN        463    465       {ECO:0000244|PDB:3V98}.
FT   HELIX       470    493       {ECO:0000244|PDB:3V98}.
FT   HELIX       497    501       {ECO:0000244|PDB:3V98}.
FT   HELIX       504    515       {ECO:0000244|PDB:3V98}.
FT   TURN        516    520       {ECO:0000244|PDB:3V98}.
FT   HELIX       522    524       {ECO:0000244|PDB:3V98}.
FT   HELIX       533    547       {ECO:0000244|PDB:3V98}.
FT   HELIX       549    555       {ECO:0000244|PDB:3V98}.
FT   HELIX       558    562       {ECO:0000244|PDB:3V98}.
FT   HELIX       565    567       {ECO:0000244|PDB:3V98}.
FT   STRAND      572    574       {ECO:0000244|PDB:3O8Y}.
FT   STRAND      579    581       {ECO:0000244|PDB:3V98}.
FT   HELIX       585    591       {ECO:0000244|PDB:3V98}.
FT   HELIX       595    608       {ECO:0000244|PDB:3V98}.
FT   HELIX       629    653       {ECO:0000244|PDB:3V98}.
FT   HELIX       665    667       {ECO:0000244|PDB:3V98}.
FT   STRAND      669    671       {ECO:0000244|PDB:3V98}.
SQ   SEQUENCE   674 AA;  77983 MW;  36F38C0A9E86BB21 CRC64;
     MPSYTVTVAT GSQWFAGTDD YIYLSLVGSA GCSEKHLLDK PFYNDFERGA VDSYDVTVDE
     ELGEIQLVRI EKRKYWLNDD WYLKYITLKT PHGDYIEFPC YRWITGDVEV VLRDGRAKLA
     RDDQIHILKQ HRRKELETRQ KQYRWMEWNP GFPLSIDAKC HKDLPRDIQF DSEKGVDFVL
     NYSKAMENLF INRFMHMFQS SWNDFADFEK IFVKISNTIS ERVMNHWQED LMFGYQFLNG
     CNPVLIRRCT ELPEKLPVTT EMVECSLERQ LSLEQEVQQG NIFIVDFELL DGIDANKTDP
     CTLQFLAAPI CLLYKNLANK IVPIAIQLNQ IPGDENPIFL PSDAKYDWLL AKIWVRSSDF
     HVHQTITHLL RTHLVSEVFG IAMYRQLPAV HPIFKLLVAH VRFTIAINTK AREQLICECG
     LFDKANATGG GGHVQMVQRA MKDLTYASLC FPEAIKARGM ESKEDIPYYF YRDDGLLVWE
     AIRTFTAEVV DIYYEGDQVV EEDPELQDFV NDVYVYGMRG RKSSGFPKSV KSREQLSEYL
     TVVIFTASAQ HAAVNFGQYD WCSWIPNAPP TMRAPPPTAK GVVTIEQIVD TLPDRGRSCW
     HLGAVWALSQ FQENELFLGM YPEEHFIEKP VKEAMARFRK NLEAIVSVIA ERNKKKQLPY
     YYLSPDRIPN SVAI
//
